The findings that type I IFNs induced by bacterial sepsis leads to DC-mediated suppression of cellmediate immunity are interesting and add to the growing knowledge of the role of type I IFNs in immunity. The authors only use cytotoxicity as a read-out for immunity, which is a good functional assay, but they need to determine the actual number of CD8+ T-cells using either ICS and/or tetramers.
Specific Comments Figure 1:
A and B. The authors use bioluminescence imaging data to determine bacterial burden however they don't indicate how this data correlates with actual bacterial numbers. Additionally, in Supplemental Figure 1 , (lines 101-103) they state that sham-treated mice showed less bacterial translocation than CASP-treated mice however they do not directly compare the bacterial numbers of the sham-treated mice to CASP-treated mice. More importantly it would be useful to see the kinetics of E. coli clearance. Do CASP-treated mice still harbor bacteria at the time adenovirus challenge? If so, it would be interesting to examine immunity in the absence of bacterial infection, perhaps by treating the mice with antibiotics.
C. It is unclear if the untreated mice were subjected to CASP. If so, why wouldn't normal bacterial flora in the colon induce this response. Please clarify.
G. This assay was not sensitive enough to support the argument that immune paralysis is localized to the spleen and should either not be included or a better control should be used.
H. The authors should compare cytotoxicity with bacterial burden at each day. It would be interesting to see whether there is an intermediate phenotype a 3 days following sepsis. The authors claim that suppression of cytotoxicity is a result of TLR4 but not TLR2 signaling (C), however Pam3Cys, a TLR2 ligand, is able to induce this suppression (A). The discussion of this discrepancy (lines 160-163) requires more depth. Is it possible that Pam3Cys-mediated suppression is due to IL-10? If so, the authors should show that Pam3Cys treated mice no longer show immune paralysis in the absence of MyD88 and IL-10. In order to confirm that type I IFNs are responsible for the suppression of cytotoxicity following sepsis, the authors should include an experiment in which mice are treated with recombinant IFNα/β prior to adenoviral challenge to show that type I IFN is sufficient to block immunity. C. The authors state that type I IFN suppresses cross-priming (lines 213-217), however type I IFN have been shown to induce cross-priming in vivo (Le Bon et al. 2003 Nat. Immunol. 4:1009 . This is a huge discrepancy, one which the authors need to discuss. E. The authors fail to mention that OVA peptide they are using is E15R (line 234) which makes understanding this experiment confusing. Line 265 should read "lung-draining lymph nodes" and not "skin" D. and E. The authors need to include the control that at day 7 post injection of clodronate liposomes that macrophages are depleted while DCs have recovered. In addition, it should be explained why is the CASP model of sepsis not being used in macrophage-depleted mice. This manuscript provides evidence that experimentally -induced sepsis in mice inhibits the development of antigen-specific T cells in a subsequent infection with viral or bacterial pathogens. The suppressive effect is shown to result from TLR4-TRIF-IRF3/7 signaling by splenic macrophages, resulting in the production of type I IFN. DC are the main targets of the suppressive type I IFN activity as suggested by the reduced ability of splenic DC to cross-present antigen.
The work presented in this manuscript is consistent with earlier work by the same group and others that type I IFN-although major antiviral cytokines-can under specific circumstances suppress adaptive immunity to viral pathogens. Although the work presented here strongly supports this suppressive activity, the concept of type I IFN suppressing antiviral immunity is counterintuitive and seemingly at odds with many reports showing an enhancement of antigen presentation and a support of adaptive immunity by type I IFN. The authors are aware of this and present some challenging ideas why and how type I IFN may exert opposing effects on the development of T cellmediated immunity. Unfortunately, none of these ideas is being tested. For example, the authors speculate about the importance of timing IFN production with respect to the onset of adaptive immunity. Longman et al. suggest suppression of DC IL-12 production may be relevant for the inhibitory IL-12 effect. Using recombinant cytokine the authors could test whether application of IFN at different times before or after infection causes opposing effects on the development of antiviral T cells and whether an inhibitory activity of IFN can be rescued by applying IL-12. Another point that doesn't become clear is the localization of the suppressive type I IFN effect to the spleen. In their sepsis model bacteria should be found in lymph nodes as well and if suppression of antigen presentation does not occur in these organs why is the adaptive immune response to virus almost entirely inhibited? Does this depend on the route of entry of the pathogen?
Specific comments:
1. The procedure of sham operation should be described. According to figure S1 some of the shamoperated mice contain splenic E. coli. Do these animals show suppression?
2. Figure 1G shows some suppression after intranasal application. This is not described correctly in the text.
3. Figure 2A shows suppression after administration of Pam3Cys. Is this mediated by type I IFN or are there IFN-independent suppressive mechanisms? 4. Figure 4D : can the authors rule out that CD11c+ cells are involved in IFN production via an IFNAR-IRF7 feed-forward mechanism? This would similarly lead to a lack of suppressive activity. There currently exist no adequate treatment for severe sepsis. Although the early inflammatory response (SIRS) has been the frequent target for drug therapies in sepsis, there is increasing appreciation that sepsis is also associated with depressions in adaptive immunity that puts the organism at risk of secondary infections. The current study is focused on the role of TRIF and type I interferons on DC antigen presentation as it relates to T cell responses.
The questions being asked are important and the findings are novel and in some cases unexpected. The results will challenge some current dogma regarding the role that type I interferons play in sepsis.
Major concerns: 1. Many of the Methods require understanding of the models used. For instance, does the adenoviral vector allow infected cells to produce soluble ovalbumin or do infected cells produce cell bound Ovalbumin? Was a replication competent or incompetent adenoviral vector used in the experiments? How were splenic dendritic cells purified, this is not mentioned in the text? Many of the experiments are complex, and for many of them, the reader has to do background reading through references to understand these complexities within experiments.
2. Much of this study relies on the fact that sepsis is causing antigen specific immune suppression against adenovirus (expressing ovalbumin), as measured by specific responses to ovalbumin, through induction of type I interferon. However, it is known that TLR stimulation causes type I IFN production during sepsis (Weighardt et al. J Immunol. 2006 Oct 15; 177(8):5623-30, Kelly-Scumpia et al. J Exp Med. 2010 Feb 15; 207(2):319-26) . The original function of interferon as described in the early literature was interference with viral entry, replication, and infection. How can we be certain that what we are observing is not because sepsis causes an induction of a non-specific antiviral type I IFN dependent response that prevents adenoviral infection and replication within spleen cells, resulting in decreased expression of ovalbumin for CTLs to respond to? Experiments examining ovalbumin levels following infection or cell bound Ovalbumin levels (depending on how expression of ovalbumin is accomplished) and viral plaque forming units from the spleen of sham or septic mice will help determine whether splenocytes are more or less resistant to adenoviral infection in septic mice.
3. The model is a difficult one to understand. How is a viral infection following bacterial sepsis clinically relevant? CTL responses are important against viruses and tumors. One can argue what you are seeing is a shift in the host immunity to more humoral responses which will protect against the main pathogen invading the organism and less towards CTL responses because the CTL responses are no longer important. One can argue that you are observing decreased bystander immunity to an irrelevant pathogen which would be neglected during a massive host response to protect against the primary, and more threatening, pathogen. It would be interesting to see if an E. coli expressing Ova was used, what happens to adenovirus-Ova CTL responses. Furthermore it would be interesting to see if CTL and humoral immunity to Ova would be differentially affected during that situation. It should also be noted in the text that you are mainly examining bystander immunity, and not immunity related to the host pathogen. This reviewer does note that bystander immunity is also important to secondary pathogens, and decreased bystander humoral immunity has been noted in many models of sepsis previously.
A few other issues bear discussing, possibly with additional experiments being required. 4. First, there is a very large body of evidence spanning over two decade that type I IFN or toll-like receptor signaling is necessary and sufficient to cause dendritic cell maturation, resulting in induction of T cell dependent immunity and CTL responses (noteworthy is J Immunol. 2005 Jul 15;175(2):839-46 which shows that a TLR4-TRIF dependent pathway is essential for DC maturation following E. coli infection). You are contending that in your model, the opposite is happening, that type I IFN induced by the TLR4-TRIF pathway is causing suppression of DC mediated CTL responses. How do you reconcile these obvious differences? Did you examine what happens to DCs in your model, whether they are matured, depleted (through apoptosis), or activated? What happens to DCs in your model of sepsis and are DC mediated responses important in sepsis? In other models of sepsis, as well as in human disease, DCs are depleted due to apoptosis. Could it be that sepsis is causing apoptosis of DCs and that is why there is a lack of CTL responses following sepsis? Given the above reference, it could be that TRIF and type I IFN are mediating apoptosis of DCs, and due to the absence of DCs, the splenic T cells cannot respond to systemic adenovirus.
5. There is now a large body of evidence that IL-10 production is dependent on type I interferon (J Immunol. 2010 Dec 1;185(11):6599-607; J Immunol. 2007 Jun 1;178(11):6705-9, Immunity. 2011 Feb 25;34(2):213-23). You are suggesting that IL-10 is only MyD88 dependent. Given you are suggesting a TLR4-TRIF-type I IFN dependent pathway is participating in the immunosuppressive pathways observed, but suggesting it is IL-10 independent, you should actually investigate this, as this is the only immunosuppressive pathway identified thus far that is type I IFN dependent.
In other words we are not fully convinced that type I IFN alone is causing suppression of DC responses to secondary infection.
Minor comments
The language of "Gram negative sepsis." The model is a model of polymicrobial sepsis in which they are adding a specific gram negative bacteria to be able to track that specific bacteria. Many other bacteria and microorganisms are also contributing to the infection.
For Figure 4B : How were splenic DCs for co-culture experiments purified? What was the purity of these DCs? What was the percentage of living DCs between the different groups, as sepsis is known to induce apoptosis of the majority of DCs in the spleen? It is possible that the purified fraction of DCs from the spleen of septic mice contain a considerable portion of apoptotic DCs, and that is the reason that IL-2 production was considerably diminished by Ad-Ova.
Similarly for Figure 4C and 4G: Did the 16 hour culture of BM DCs cause maturation of DC in culture. It is known that once matured, DCs are less capable of certain types of antigen uptake such as micro-and macro-pinocytosis, and only utilize endocytosis for antigen uptake, which may be affecting their abilitiy to take up adenovirus and alter their ability to present antigen (Proc Natl Acad Sci U S A. 2010 Mar 2;107 (9) Answer: The experiment asked for by the referee has already been included in the manuscript. In Figure 4a , we have shown pentamer stainings of OVA-specific CD8 T cells. Answer: The points raised by the referee are well taken. However, to study the effect of systemic bacteria on the generation of adaptive immunity quantitatively and not only qualitatively we used a well accepted model for (Gram-negative) sepsis, i.e. intravenous injection of E.coli (Buras et al. Nat Rev Drug Discov 2005) . This model allowed us to investigate the effect of a defined dose of wt or genetically modified (e.g. luciferase) bacteria. We agree, however, with the reviewer that it would be interesting to investigate the mechanisms underlying septic immune paralysis by using the CASP model. However, the CASP model is a complex model requiring surgery and large numbers of animal in experiments, as about 50-60% of the mice die during septic shock. While less of a problem for wt mice, many of the knock-out and transgenic animals used in our study were not available at sufficient numbers.
Specific Comments
To answer the questions by the referee we performed additional experiments using heat killed (HK) E.coli and further treated mice injected with E.coli with antibiotics. As suppression of CTL activity induced by injection of HK E.coli or after treatment of E.coli-infected mice with antibiotics was as strong as after injection of living bacteria or after CASP, we concluded that already a short bolus of systemic bacteria is capable to induce suppression of CTL immunity. This demonstrates that suppression of CTL immunity does not require the persistent presence of bacteria. These data have been included in the manuscript (new supplementary Figure 2) .
Question: C. It is unclear if the untreated mice were subjected to CASP. If so, why wouldn't normal bacterial flora in the colon induce this response. Please clarify.
Answer: We want to apologize for incompletely describing the experiment. The points addressed by the referee have been clarified in the manuscript (results and material and methods). In short, "untreated" meant undergoing no stent peritonitis, i.e. intestines of mice were only touched with cotton swabs without setting a stent therefore mimicking the complex surgical procedure during CASP treatment.
Regarding the point whether normal bacterial flora was suppressive, the referee is right, normal intestinal flora causes suppression of CTL immunity. As during CASP normal gut bacteria enter the peritoneum and thereafter the circulation, our data gained from mice developing CTL suppression after surviving CASP indeed show that "normal gut bacteria" can cause immune suppression.
Question: G. This assay was not sensitive enough to support the argument that immune paralysis is
localized to the spleen and should either not be included or a better control should be used.
Answer: We agree that the CTL response induced by intranasal infection of Adeno-OVA is much lower than that induced by i.v. infection. This low CTL response after intranasal compared to intravenous adenoviral infection may be caused by various factors, which we will not be able to address in a satisfactory fashion in this manuscript. Therefore, we have taken this figure out. Accordingly, the statements on localization of suppression of CTL immunity have been amended.
Question: H. The authors should compare cytotoxicity with bacterial burden at each day. It would be interesting to see whether there is an intermediate phenotype a 3 days following sepsis.
Answer: We are thankful for making us aware of the fact that we had forgotten to include this important data set. Data for "day 3 after E.coli injection" have been included in the new Figure 1D . At day 3 suppression of CTL activity is still complete. 
Answer:
The point by the referee is well taken, as it was indeed unexpected that TLR4 was the only receptor required to transmit suppressive signals after systemic injection of E.coli. Given this discrepancy between isolated TLR-Ligands and "a whole organism" (E.coli), our data (as well as those by Roger et al. PNAS 2009) suggest that TLR2-Ligands present in E.coli are not "visible" to the immune system and therefore do not cause CTL suppression. However, as suggested by the referee, we generated data demonstrating that suppression induced by Pam3Cys was dependent on MyD88, but did not depend on IL-10 or type I IFN (new Figure 3c) . This finding stresses the difference of isolated TLR-ligands vs entire bacteria.
We have further added new data showing that the TLR9-ligand CpG-DNA was dependent on MyD88, but like Pam3Cys was not dependent on IL-10 or type I IFN (new Figure 3c ). (Le Bon et al. 2003 Nat. Immunol. 4:1009 . This is a huge discrepancy, one which the authors need to discuss. Figure 4b) .
Question: E. The authors fail to mention that OVA peptide they are using is E15R (line 234) which makes understanding this experiment confusing.
We apologize for this misunderstanding. Although the peptide is already described in the figure legend to Fig 4e, we have additionally clarified the description of the peptide in the results. Answer: As the suppressive effect by systemic bacteria was time and dose-dependent, using defined numbers of E.coli allowed us to study the underlying mechanism in quantitative terms. As mentioned above, this approach allowed us to study the suppressive activity of TLR4-ligands in a quantitative fashion.
Question: Lines 273-274: The authors do not show that macrophages directly transfer antigen to CD8+ DCs and thus should not claim their data proves this
Answer: The transfer of antigen from metallophilic marginal zone macrophages (MMM) to CD8+DC has recently been published by us (Backer et al. PNAS 2010) . We never intended to say that the data provided in this manuscript proves that antigen is transferred from macrophages to DCs.
Question: Lines 276-278: This statement is subjective and should be removed.
Answer: We agree. Has been removed.
Question: The figure legends for Supplemental Figure 3 and 4 are switched and inadequately describe the experiments. The figure legend for Supplemental Figure 3 does not mention what the control samples are and what the black lines in the histograms depict. The figure legend for Supplemental Figure 4 makes no mention of using an anti-CD4 depleting antibody.
Answer: Thank you again, all changes have been made as suggested.
Referee #2 (Remarks to the Author):
This manuscript provides evidence that experimentally -induced sepsis in mice inhibits the development of antigen-specific T cells in a subsequent infection with viral or bacterial pathogens. The suppressive effect is shown to result from TLR4-TRIF-IRF3/7 signaling by splenic macrophages, resulting in the production of type I IFN. DC are the main targets of the suppressive type I IFN activity as suggested by the reduced ability of splenic DC to cross-present antigen.
Question: The work presented in this manuscript is consistent with earlier work by the same group and others that type I IFN-although major antiviral cytokines-can under specific circumstances suppress adaptive immunity to viral pathogens. Although the work presented here strongly supports this suppressive activity, the concept of type I IFN suppressing antiviral immunity is counterintuitive and seemingly at odds with many reports showing an enhancement of antigen presentation and a support of adaptive immunity by type I IFN.
Answer: We are aware of this seeming discrepancy and agree that it is very important to clarify this point. We have included new experimental evidence that application of E.coli or even recombinant type I IFN before but not after adenovirus infection suppresses CTL immunity (new Figure 4a right  panel and 4b) . This clearly demonstrates that timing of exposure to type I IFN is the critical parameter defining the quality of IFN-responses.
As suggested by the referee the point has been discussed in more depth in the manuscript. In short, our findings are in line with reports by others (e. Figure 4a and 4b) . We have also demonstrated that incubation of DCs with type I IFN reduces subsequent cross-presentation to CTLs (Figure 4e ). Therefore, type I IFN is not suppressive per se, but only exerts suppressive properties if present before antigen encounter. Type I IFN treated DCs produce less IL-12, which may play a role in the lack of CTL immunity observed here. Supplementation of IL-12 in the experiments, however, led to severe side effects causing death of such treated animals and prevented us from examining the relevance of this mediator in rescue from type I IFN-induced suppression of CTL immunity.
Question: Using recombinant cytokine the authors could test whether application of IFN at different times before or after infection causes opposing effects on the development of antiviral T cells and whether an inhibitory activity of IFN can be rescued by applying IL-12.
Answer: As suggested by the referee we performed experiments with recombinant type I IFN. Like E.coli, injection of recombinant IFN I injected before AdOVA infection significantly suppressed CTL immunity (new Figure 4b) . Injection of recombinant IFN I after Adenovirus infection did not change ensuing CTL immunity (new Figure 4b) . Therefore, this experiment shows the differential effect of type I IFN on CTL immunity. Rescue of CTL suppression by IL-12 was not successful because mice died from the well-known complications of IL-12 therapy. Although we cannot formally exclude a crucial role of IL-12 in our model, this result provides further evidence for the difficulty in using IL-12 as a therapeutic agent.
Question: Another point that doesn't become clear is the localization of the suppressive type I IFN effect to the spleen.
Answer: The generation of CTL immunity against Adenovirus has been shown to require the spleen and therein transfer of antigen from metallophilic marginal zone macrophages to CD8+DCs (Backer et al PNAS 2010) . We therefore assume that mechanisms affecting Adenovirus-specific CTL immunity operate in the spleen. Our assumption is in line with clinical data strongly associating septic immune paralysis with the spleen (Hotchkiss and Karl, NEJM 2003) .
Question: In their sepsis model bacteria should be found in lymph nodes as well and if suppression of antigen presentation does not occur in these organs why is the adaptive immune response to virus almost entirely inhibited? Does this depend on the route of entry of the pathogen?
Answer: Indeed, after CASP bacteria were found in lymph nodes (LN) draining the gut (mesenteric LN) and the peritoneum (celiac, periportal LN) (data not shown). The same was true after intestinal manipulation, which served as a control for CASP. However, after intravenous injection of E.coli, no such distribution to LNs was observed.
As we found bacteria in mesenteric LN after mock operation (intestinal manipulation of the gut), but did NOT observe suppression of CTL activity, the presence of bacteria in (mesenteric) LN obviously did not cause suppression of CTL immunity. The presence of bacteria in the spleen, where adenovirus-specific CTL immunity is generated, was predictive of suppression of CTL immunity. The clinical relevance of our finding was reiterated by the observation that also CTL immunity against blood-borne HSV, Influenza, Listeria and soluble OVA turned out to be spleen-dependent, suggesting that CTL responses against many systemic infections are affected during sepsis.
The main point of our manuscript, however, is that type I IFN acts on CTL immunity being generated within the spleen. We do not want to exclude that circulating type I IFN may have similar effects at other sites and we do not strengthen the point that only type I IFN produced locally in the spleen has suppressive activity. Therefore, even type I IFN generated at other sides will have suppressive activity, because injection of recombinant type I IFN efficiently blocks CTL immunity(now in new Figures 4b).
Question: 6. No source or reference is given for IRF3/7 dko mice
Answer: IRF3/7 dko mice are the result of crossing IRF3 and IRF7 KO mice. References therefore are the ones for the individual IRF KOs.
Referee #3 (Remarks to the Author):
There currently exist no adequate treatment for severe sepsis. Although the early inflammatory response (SIRS) has been the frequent target for drug therapies in sepsis, there is increasing appreciation that sepsis is also associated with depressions in adaptive immunity that puts the organism at risk of secondary infections. The current study is focused on the role of TRIF and type I interferons on DC antigen presentation as it relates to T cell responses.
Major concerns:
Question: 1. Many of the Methods require understanding of the models used. For instance, does the adenoviral vector allow infected cells to produce soluble Ovalbumin or do infected cells produce cell bound Ovalbumin? Was a replication competent or incompetent adenoviral vector used in the experiments? How were splenic dendritic cells purified, this is not mentioned in the text? Many of the experiments are complex, and for many of them, the reader has to do background reading through references to understand these complexities within experiments.
Answer: The adenoviral vector (Ad 5) is a gutless, replication incompetent viral vector. Therefore, after integration no new virus can be generated. The adenoviral vector (AdOVA) expresses OVA, which is not secreted. OVA is only released from cells after necrosis.
The protocol for the generation of splenic DC has now been included in the material and methods section. (Weighardt et al. J Immunol. 2006 Oct 15; 177(8):5623-30, Kelly-Scumpia et al. J Exp Med. 2010 Feb 15; 207(2) 
Question: 2. Much of this study relies on the fact that sepsis is causing antigen specific immune suppression against adenovirus (expressing ovalbumin), as measured by specific responses to ovalbumin, through induction of type I interferon. However, it is known that TLR stimulation causes type I IFN production during sepsis

:319-26). The original function of interferon as described in the early literature was interference with viral entry, replication, and infection. How can we be certain that what we are observing is not because sepsis causes an induction of a nonspecific antiviral type I IFN dependent response that prevents adenoviral infection and replication within spleen cells, resulting in decreased expression of ovalbumin for CTLs to respond to? Experiments examining ovalbumin levels following infection or cell bound Ovalbumin levels (depending on how expression of ovalbumin is accomplished) and viral plaque forming units from the spleen of sham or septic mice will help determine whether splenocytes are more or less resistant to adenoviral infection in septic mice.
Answer: The point made by the referee is well taken. As we consider this point as highly important, it has been addressed in the manuscript in more detail. Most importantly, the suppressive effect of E.coli on the generation of CTL immunity is not simply due to a reduced infectivity and thus lower numbers of antigen available for T cell activation. This conclusion is based on the following experiments: Mice receiving soluble OVA or antibody-OVA complexes directly targeting OVA to CD8+DCs (anti-DEC205-OVA) show also a lack of OVAspecific CTL immunity after challenge with E.coli (new Figure 1g and old Figure 5e Answer: Of course, such experiments would be very interesting, but should be conducted within the scope of a separate manuscript studying the importance of CTL immunity against bacteria. We are not aware of a large body of experimental evidence that supports the argument that CTL immunity plays a dominant role against an extracellular bacterium. While intracellular persistence of some strains of E.coli has been noted at certain sites such as uroepithelial cells in the bladder or macrophages in the bone marrow, very few reports exist on the relevance of CTL immune surveillance of such infections. Our focus in this manuscript is the impact of type I IFN, induced by bacterial infection, on induction of adaptive CTL immunity. We are puzzled by the terminology (bystander immunity) used by the referee. We are studying antigen-specific CTL immunity using recombinant viruses as molecularly defined infectious agents. The impact of a first infection on a subsequent infection is something that has been addressed in the past by well-known groups in the field of immunology, such the group of Rolf Zinkernagel (Navarini et al PNAS 2006, and Navarini et al. PNAS 2009) . Antigen-specific immunity by definition cannot be bystander immunity, because it is always directed against a defined molecular target, i.e. antigen. This we have studied here in this manuscript. Therefore, the terminology bystander is misleading and should not be used. According to the reviewer´s suggestion we have performed a series of experiments, which have been included into the revised manuscript. These are: upon challenge with E.coli there is no deletion of DCs in the spleen (new supplementary Figure 4) ; splenic DCs are partially matured but fail to express proinflammatory cytokines (new Figure 4d) ; injection of recombinant type I IFN suppressed CTL activity (new figure 4b) . These data clearly demonstrate that the lack of CTL immunity cannot be explained by deletion of DCs in the spleen.
Question: 5.
There is now a large body of evidence that IL-10 production is dependent on type I interferon (J Immunol. 2010 Dec 1; 185(11):6599-607; J Immunol. 2007 Jun 1; 178(11):6705-9, Immunity. 2011 Feb 25; 34(2):213-23 Figure 3a that IL-10 is not involved in the suppression of CTL immunity described here. This does not exclude that type I IFN can induce IL-10, but clearly demonstrates that IL-10 does not play a role in our model reported here. The statement that IL-10 is MyD88 dependent is misleading and therefore will be rephrased. Answer: Protocols describing the isolation procedure for splenic DCs have been now included into the manuscript. As mentioned above, when using E.coli no apoptosis in DCs was observed (new supplementary Figure 4) . Therefore, effects reported here were due to cell-intrinsic changes in the DCs rather than their elimination by apoptosis. Figure 4C and . 2010 Mar 2; 107(9):4287-92, Garrett et al. Cell 2000 Aug 4(102) 3, 325-334) . and that can explain the diminished IL-2 production Answer: As described in supplementary Figure 5 , type I IFN-treated DCs did not differ from control DCs with respect to MHC expression and antigen uptake. This excludes that lower antigen uptake or MHC expression levels were responsible for reduced antigen presentation in type I IFN treated DCs (Figure 4e ). Rather our data imply that type I IFN negatively regulates the capability of DCs to cross-present endocytosed antigens.
Minor comments
Question: Similarly for
Question: Where were OT-I and OT-II mice obtained from?
Answer: Mice were provided by Christian Kurts who is coauthor on this manuscript.
Question: Line 115-the word "Where" should be changed to "were".
Answer: Has been changed.
Question: Line 101 in results-Is it interesting or expected that Sham treated mice did not develop dissemination of bacteria or impairment of CTL responses?
Answer: It was interesting, because this experiment suggested that for induction of suppression bacteria had to disseminate to the spleen and that translocation of bacteria per se was not suppressive.
Question: Line 269 Clodrinate is misspelled.
Answer: Has been changed Thank you for submitting your revised manuscript to the EMBO Journal. Your manuscript has now been seen by the original referee #2. As you can see below, the referee appreciates the introduced changes and supports publication here. I am therefore pleased to proceed with the acceptance of the paper for publication here. Before doing so, there are two issues that have to be resolved -see below. Both issues can be resolved with text changes. Once we receive the revised version we will proceed with its acceptance.
Thank you for submitting your interesting study to the EMBO Journal.
